- In mice and hamster study, COVID-19 therapies comprising two types of antibodies were found to be effective against a wide range of COVID-19 variants, Reuters reported citing the Washington University School of Medicine.
- The latest study included three of the four variants that have been designated “variants of concern” by the WHO.
- The FDA in April revoked the emergency use authorization of Eli Lilly And Co’s (NYSE:LLY) single antibody therapy, bamlanivimab, amid resistance due to the variants.
- The researchers evaluated the FDA authorized combination therapies made by Regeneron Pharmaceuticals Inc (NASDAQ:REGN), Eli Lilly, and single antibody therapy, sotrovimab by Vir Biotechnology Inc (NASDAQ:VIR) and GlaxoSmithKline Plc (NYSE:GSK).
- They also assessed the antibodies in clinical trials by AbbVie Inc (NYSE:ABBV), Vir, and AstraZeneca Plc (NASDAQ:AZN).
Dual-Antibody Cocktail Shows Effectiveness In COVID-19 Animal Models: Reuters
In mice and hamster study, COVID-19 therapies comprising two types of antibodies were found to be effective against…
